Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07284890 (ARRY-461) in BRAF V600 mutant solid tumors
NCT04543188Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of tinlorafenib in melanoma, non-small cell lung cancer (NSCLC) and brain neoplasms (9 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events and 6 more. Started Jan 2021; status: terminated.
02
Drugs
tinlorafenib
03
Conditions
melanomanon-small cell lung cancer (NSCLC)brain neoplasms
Beyond the preview
Go deeper on NCT04543188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543188.